MLYS on Nasdaq
Mineralys Therapeutics, Inc.
Pharmaceutical preparations company based in Radnor, listed on Nasdaq (MLYS).
Price unavailable
Last updated Oct 18, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $132.0M | $168.6M |
| General and administrative | $38.6M | $23.8M |
| Total operating expenses | $170.6M | $192.4M |
| Loss from operations | -$170.6M | -$192.4M |
| Interest income, net | $16.0M | $14.6M |
| Other income | $0 | $5.0K |
| Total other income, net | $16.0M | $14.6M |
| Net loss | -$154.7M | -$177.8M |
| Net loss per share attributable to common stockholders - basic (in USD per share) | -$2.29 | -$3.66 |
| Net loss per share attributable to common stockholders - diluted (in USD per share) | -$2.29 | -$3.66 |
| Weighted-average shares used to compute net loss per share attributable to common stockholders - basic (in shares) | 67.7M shares | 48.5M shares |
| Weighted-average shares used to compute net loss per share attributable to common stockholders - diluted (in shares) | 67.7M shares | 48.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-02-28 |
|---|---|---|---|---|
| Cash and cash equivalents | $172.9M | $114.1M | ||
| Investments | $483.7M | $84.1M | ||
| Prepaid and other current assets | $4.8M | $7.2M | ||
| Total current assets | $661.4M | $205.4M | ||
| Property and equipment, net | $38.0K | $53.0K | ||
| Other assets | $382.0K | $499.0K | ||
| Total assets | $661.8M | $205.9M | ||
| Accounts payable | $2.0M | $479.0K | ||
| Accrued liabilities | $13.1M | $14.2M | ||
| Total current liabilities | $15.1M | $14.6M | ||
| Common stock, $0.0001 par value; 500,000,000 shares authorized as of December 31, 2025 and 2024; 81,536,557 and 49,821,915 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $8.0K | $5.0K | ||
| Additional paid-in capital | $1.1B | $493.8M | ||
| Accumulated deficit | -$457.2M | -$302.5M | ||
| Total stockholders equity | $646.7M | $191.3M | $241.2M | |
| Total liabilities and stockholders equity | $661.8M | $205.9M | ||
| Common stock par value (in USD per share) | $0.00 | $0.00 | ||
| Common stock shares authorized (in shares) | 500.0M shares | 500.0M shares | 500.0M shares | |
| Common stock shares issued (in shares) | 81.5M shares | 49.8M shares | ||
| Common stock shares outstanding (in shares) | 81.5M shares | 49.8M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2023-02-28 |
|---|---|---|---|---|
| Cash and cash equivalents | $172.9M | $114.1M | ||
| Investments | $483.7M | $84.1M | ||
| Prepaid and other current assets | $4.8M | $7.2M | ||
| Total current assets | $661.4M | $205.4M | ||
| Property and equipment, net | $38.0K | $53.0K | ||
| Other assets | $382.0K | $499.0K | ||
| Total assets | $661.8M | $205.9M | ||
| Accounts payable | $2.0M | $479.0K | ||
| Accrued liabilities | $13.1M | $14.2M | ||
| Total current liabilities | $15.1M | $14.6M | ||
| Common stock, $0.0001 par value; 500,000,000 shares authorized as of December 31, 2025 and 2024; 81,536,557 and 49,821,915 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $8.0K | $5.0K | ||
| Additional paid-in capital | $1.1B | $493.8M | ||
| Accumulated deficit | -$457.2M | -$302.5M | ||
| Total stockholders equity | $646.7M | $191.3M | $241.2M | |
| Total liabilities and stockholders equity | $661.8M | $205.9M | ||
| Common stock par value (in USD per share) | $0.00 | $0.00 | ||
| Common stock shares authorized (in shares) | 500.0M shares | 500.0M shares | 500.0M shares | |
| Common stock shares issued (in shares) | 81.5M shares | 49.8M shares | ||
| Common stock shares outstanding (in shares) | 81.5M shares | 49.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$154.7M | -$177.8M |
| Accretion of discount on held-to-maturity securities | -$9.9M | -$9.4M |
| Stock-based compensation | $19.3M | $11.3M |
| Depreciation and amortization | $59.0K | $43.0K |
| Accrued interest receivable | -$166.0K | $424.0K |
| Prepaid, other current assets, and other assets | $2.5M | $4.9M |
| Accounts payable and accrued liabilities | $427.0K | $4.2M |
| Net cash used in operating activities | -$142.4M | -$166.3M |
| Purchases of marketable securities | -$814.7M | -$373.4M |
| Maturities of marketable securities | $425.0M | $488.5M |
| Purchases of property and equipment | -$15.0K | -$96.0K |
| Net cash provided by (used in) investing activities | -$389.8M | $115.0M |
| Proceeds from stock option exercises | $12.8M | $297.0K |
| Proceeds from issuance of common stock for cash under employee stock purchase plan | $243.0K | $221.0K |
| Payment of shelf offering costs | -$391.0K | -$435.0K |
| Proceeds from issuance of common stock and pre-funded warrants in a private placement offering, net of offering costs | $0 | $116.1M |
| Net cash provided by financing activities | $591.0M | $116.1M |
| Net increase in cash and cash equivalents | $58.8M | $64.8M |
| Offering costs included in accounts payable and accrued liabilities | $41.0K | $0 |
No quarter-by-quarter statement was filed.
Leadership
Who has led Mineralys Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
2025
- Chief executive officerJon Congleton Feb 9, 2023 to now8
Board members and other officers (15)
- Chief Commercial OfficerEric Warren Mar 4, 2026 to now9
- Chief Medical OfficerJames J. Ferguson Iii. Aug 12, 2026 to now10
- Chief Medical OfficerDavid Malcom Rodman Feb 9, 2023 to now11
- Board memberAlexander M. Gold Jun 17, 2024 to now12
- Board memberAlexander Asam Feb 9, 2023 to Feb 13, 202313
- Board memberBrian Taylor Slingsby Feb 9, 2023 to now14
- Board memberDerek Dirocco Feb 9, 2023 to now15
- Board memberJon Congleton Feb 9, 2023 to now8
- Board memberOlivier Litzka Feb 9, 2023 to May 23, 202416
- Board memberPeter Kolchinsky Feb 9, 2023 to now17
- Board memberRajeev M. Shah Feb 9, 2023 to now17
- Board memberSrinivas Akkaraju Feb 9, 2023 to now18
- Board memberTakeshi Takahashi Feb 9, 2023 to Jul 14, 202319
- Board memberDaphne Karydas Sep 14, 2023 to now20
- Board memberGlenn Sblendorio Sep 14, 2023 to now21
Timeline
- Feb 9, 2023New chief executive Jon Congleton becomes CEO8
Filings
400 filings to the SEC since October 2021: 4 annual reports, 11 quarterly reports, 46 major events, 176 insider forms, 23 large holders, 1 private raises, 139 other. The latest 20:
- Oct 13, 2026144 EDGAR
- Oct 2, 20264 EDGAR
- Sep 30, 2026144 EDGAR
- Sep 24, 20264 EDGAR
- Sep 22, 2026144 EDGAR
- Sep 22, 20264 EDGAR
- Sep 21, 2026144 EDGAR
- Sep 17, 2026144 EDGAR
- Sep 17, 20264 EDGAR
- Sep 15, 2026144 EDGAR
- Sep 14, 2026144 EDGAR
- Sep 9, 2026144 EDGAR
- Aug 25, 20264 EDGAR
- Aug 21, 2026144 EDGAR
- Aug 17, 2026144 EDGAR
- Aug 13, 2026144 EDGAR
- Aug 12, 20264 EDGAR
- Aug 12, 20263 EDGAR
- Aug 12, 20264 EDGAR
- Aug 11, 202610-Q EDGAR
The 400 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 23 such filings since October 2021, the latest 10:
- Aug 6, 2026SCHEDULE 13G/A
- Feb 13, 2026SCHEDULE 13G/A
- Feb 5, 2026SCHEDULE 13G
- Jan 21, 2026SCHEDULE 13G
- Sep 8, 2025SCHEDULE 13D/A
- Sep 8, 2025SCHEDULE 13D/A
- Aug 14, 2025SCHEDULE 13G/A
- Aug 14, 2025SCHEDULE 13G/A
- Mar 17, 2025SCHEDULE 13D/A
- Mar 17, 2025SCHEDULE 13D/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
- Jun 1, 2022Raised $118 million in a private offering of equity Form D: 23 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Catalys Pacific, LLC | 7,903,838 | $213.2M | 92.9% | No change |
| Ra Capital Management, L.P. | 7,692,750 | $207.6M | 1.8% | No change |
| BlackRock, Inc. | 5,887,038 | $158.8M | 0.0% | +1,405,456 |
| Samsara Biocapital, LLC | 5,871,018 | $158.4M | 13.0% | No change |
| Fmr LLC | 4,511,689 | $121.7M | 0.0% | −349,415 |
| State Street Corp | 4,141,636 | $111.7M | 0.0% | +1,205,696 |
| Deerfield Management Company, L.P. | 3,958,000 | $106.8M | 1.3% | New |
| Vanguard Capital Management LLC | 2,756,770 | $74.4M | 0.0% | +302,407 |
| Laurion Capital Management LP | 2,506,152 | $67.6M | 5.1% | +274,112 |
| Orbimed Advisors LLC | 2,110,300 | $56.9M | 1.1% | +57,400 |
| Capital World Investors | 1,997,607 | $53.9M | 0.0% | +1,599,428 |
| Armistice Capital, LLC | 1,736,000 | $46.8M | 1.3% | +560,000 |
| Troluce Capital Advisors LLC | 1,728,753 | $46.6M | 17.5% | +1,073,753 |
| Nantahala Capital Management, LLC | 1,640,962 | $44.3M | 1.3% | +745,481 |
| Franklin Resources Inc | 1,635,520 | $44.1M | 0.0% | −149,142 |
| Andera Partners | 1,591,917 | $42.9M | 20.8% | No change |
| Geode Capital Management, LLC | 1,584,326 | $42.8M | 0.0% | +283,191 |
| SR One Capital Management, LP | 1,563,966 | $42.2M | 4.1% | No change |
| Bank Of America Corp /de/ | 1,505,547 | $40.6M | 0.0% | +405,175 |
| Sphera Funds Management Ltd. | 1,469,971 | $39.7M | 5.7% | +130,000 |
| Goldman Sachs Group Inc | 1,458,676 | $39.4M | 0.0% | +673,633 |
| Pictet Asset Management Holding SA | 1,430,649 | $38.6M | 0.0% | +396,211 |
| Polar Capital Holdings Plc | 1,420,854 | $38.3M | 0.1% | −79,895 |
| Millennium Management LLC | 1,221,758 | $33.0M | 0.0% | +696,498 |
| Ghisallo Capital Management LLC | 1,125,000 | $30.4M | 0.7% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARAlexander M. Gold, Board member
- 13SEC EDGARAlexander Asam, Board member
- 14SEC EDGARBrian Taylor Slingsby, Board member
- 15SEC EDGARDerek Dirocco, Board member
- 16SEC EDGAROlivier Litzka, Board member
- 17SEC EDGARPeter Kolchinsky, Board member
- 18SEC EDGARSrinivas Akkaraju, Board member
- 19SEC EDGARTakeshi Takahashi, Board member
- 20SEC EDGARDaphne Karydas, Board member
- 21SEC EDGARGlenn Sblendorio, Board member